Dec. 21 at 5:54 PM
$DBVT Regarding the risk of future dilution, an article by a French analyst in the country of DBV
12/19/2025 This key clinical milestone will also trigger, by January 15th, the exercise of warrants linked to the funding obtained in 2025. The transaction, which could generate
$180 million in gross proceeds, will boost cash flow but will have a highly dilutive effect, given the biotech company's market capitalization (€705 million). Furthermore, the risk of selling pressure on the shares post-transaction is high, as a significant number of warrant holders are hedge funds not intended to remain shareholders.
